

Laura Cometi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6085401/publications.pdf>

Version: 2024-02-01

22
papers

298
citations

1039880

9
h-index

887953

17
g-index

22
all docs

22
docs citations

22
times ranked

652
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 115-120.	1.0	62
2	Calcinosis in systemic sclerosis: subsets, distribution and complications. <i>Rheumatology</i> , 2016, 55, 1610-1614.	0.9	35
3	The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. <i>Clinical Rheumatology</i> , 2020, 39, 2043-2047.	1.0	27
4	One year in review 2016: spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 3-17.	0.4	27
5	The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2096403.	1.2	21
6	Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases. <i>Clinical Rheumatology</i> , 2021, 40, 85-91.	1.0	20
7	Assessment, Definition, and Classification of Lower Limb Ulcers in Systemic Sclerosis: A Challenge for the Rheumatologist. <i>Journal of Rheumatology</i> , 2016, 43, 592-598.	1.0	17
8	Premedication prevents infusion reactions and improves retention rate during infliximab treatment. <i>Clinical Rheumatology</i> , 2016, 35, 2841-2845.	1.0	15
9	One year in review 2018: idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 937-947.	0.4	11
10	Prediction and primary prevention of major vascular complications in systemic sclerosis. <i>European Journal of Internal Medicine</i> , 2021, 87, 51-58.	1.0	9
11	The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life. <i>Clinical Rheumatology</i> , 2022, 41, 573-579.	1.0	9
12	Idiopathic inflammatory myopathies: one year in review 2021. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 199-209.	0.4	8
13	One year in review 2019: idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1-10.	0.4	7
14	Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110140.	1.2	6
15	Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110336.	1.2	6
16	Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 1310.	1.0	5
17	One year in review 2017: idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 875-884.	0.4	5
18	Oral Lactobacillus Species in Systemic Sclerosis. <i>Microorganisms</i> , 2021, 9, 1298.	1.6	4

#	ARTICLE	IF	CITATIONS
19	One year in review 2020: idiopathic inflammatory myopathies. Clinical and Experimental Rheumatology, 2021, 39, 1-12.	0.4	4
20	Treatment options in systemic sclerosis. Expert Opinion on Orphan Drugs, 2013, 1, 851-865.	0.5	0
21	Risk of malignancy and biologic therapy in rheumatic inflammatory diseases: A single-center experience. Rheumatology and Immunology Research, 2020, 1, 39-45.	0.2	0
22	One year in review 2021: idiopathic inflammatory myopathies.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0